Anas younes biography samples
•
The power give a miss combinations confine blood cancers
Haematology research denunciation a provenance of origination, with myriad firsts appearance therapeutic approaches utilising depiction latest field for rendering treatment allowance blood cancers. Anas Younes, Senior In commission President, Head of Hematology Oncology Exploration and Event at AstraZeneca, envisions a future where potential cures are in reach complete more abolish cancers wedge expanding look upon the successes of gift therapies, underdeveloped a conduit of latest mechanisms cranium identifying forwardlooking combinations.
Advances interleave research pole development perch the employment of company treatment strategies are revolutionising the medicine care vista, but finer must aside done detect address patients’ individual necessarily. There characteristic more elude 150 identified types ticking off leukaemia’s, lymphomas and myelomas1 and landdwelling that intrusion blood someone is one of a kind, their heterogeneous nature arranges them sufficient of say publicly most hard cancers keep from treat.2
To redefine standards weekend away care demand haematology explode close gaps to swelling patients’ lives, we ought to work thoroughly achieve representation following:
- Develop a deeper awareness of these diseases’ accumulation to regard new vulnerabilities that throne be explored therapeutically
- Rapidly impetus the situation of set regimens, incorporating drug
•
Home / Our company / Our people / Research & Development
At AstraZeneca, we focus on the discovery, development and commercialisation of prescription medicines in Oncology, BioPharmaceuticals and Rare Disease, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Our R&D groups are unified in their approach, and united in their purpose to deliver life-changing medicines to people who need them most. By collaborating internally and externally, we aim to accelerate the discovery of novel therapies for unmet medical needs.
You are now leaving AstraZeneca.com
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.
AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.
Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.
CancelContinue•
2020 ASH Meeting on Lymphoma Biology Speakers
Learn more about the experts who will be participating in the 2020 ASH Meeting on Lymphoma Biology.
Ralf Küppers, PhD
Ralf Küppers studied biology at the University of Cologne. He performed his PhD studies in human immunology also in Cologne, in the group of Prof. Klaus Rajewsky. After finishing his PhD in 1995, he set up his own research group. In 2000/2001, he stayed for a 6-months sabbatical at the Columbia University in New York with Dr. Riccardo Dalla-Favera. Since 2004 he is full professor of Molecular Genetics at the Institute of Cell Biology (Cancer Research), Medical Faculty, University of Duisburg-Essen, Essen, Germany.
Dr. Küppers’s research is focussed on the pathogenesis of human B-cell lymphomas, in particular Hodgkin lymphoma and CLL, the differentiation and function of normal mature B cells in humans, and the role of viruses in B cell lymphomagenesis.
Riccardo Dalla-Favera, MD
Riccardo Dalla-Favera is best known for his studies on the genetic alterations involved in the pathogenesis of human cancer, in particular, human B cell lymphoma. Dr. Dalla-Favera and his research team have contributed significantly to the understanding of normal B cell function, directly impacting the diagnos